During the past decade, Tennessee Cancer Specialists conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 12 clinical trials were completed, i.e. on average, 63.2% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 8 clinical trials were completed. i.e. 160% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tennessee Cancer Specialists" #1 sponsor was "Bristol-Myers Squibb" with 5 trials, followed by "Vanderbilt-Ingram Cancer Center" with 4 trials sponsored, "Five Prime Therapeutics, Inc." with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Novartis Pharmaceuticals" with 2 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tennessee Cancer Specialists" #1 collaborator was "National Cancer Institute (NCI)" with 4 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Tennessee Cancer Specialists" are "Breast Cancer" (4 trials), "Breast Neoplasms" (2 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Gastric Cancer" (2 trials) and "Lung Cancer" (2 trials). Many other conditions were trialed in "Tennessee Cancer Specialists" in a lesser frequency.

Most popular intervention types in "Tennessee Cancer Specialists" are "Drug" (32 trials), "Biological" (5 trials), "Device" (3 trials), "Combination Product" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (7 trials), "Placebo" (5 trials), "Erlotinib" (3 trials), "Paclitaxel" (3 trials) and "Bemarituzumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Tennessee Cancer Specialists" are 31 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Tennessee Cancer Specialists". undefined are not yet recruiting, 1 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Tennessee Cancer Specialists, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Tennessee Cancer Specialists, 4 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Tennessee Cancer Specialists has several departments that took part in Clinical trials: "Tennessee Cancer Specialists-Dowell Springs" - 8 trials